Tag: Big Pharma
-
AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
The FDA approved AbbVie’s Juvmo (tavapadon), a once-daily oral D1/D5 dopamine receptor partial agonist, for adults with Parkinson’s disease. Phase 3 TEMPO data support its efficacy, while pricing, coverage and real-world tolerability remain key commercial questions.
-
Merck’s Remigromig Meets Phase 2b/3 Endpoint in Diabetic Macular Edema
Both remigromig doses were noninferior to ranibizumab at Week 52 in the Phase 2b/3 BRUNELLO trial, but safety imbalances and commercial differentiation require further data.
-
Merck’s Remigromig Mechanism: FZD4–LRP5 Wnt Signaling in Diabetic Macular Edema
Remigromig clusters FZD4 and LRP5 to stabilize β-catenin and support CLDN5-dependent tight junctions and MFSD2A-mediated suppression of endothelial transcytosis.
-
CAPLYTA Mechanism in Bipolar Mania: Dual D2 Modulation
CAPLYTA’s exact therapeutic mechanism remains unresolved, but its proposed pharmacology combines strong serotonin 5-HT2A antagonism with distinct presynaptic and postsynaptic dopamine D2 effects. This BP Science analysis examines how that profile may regulate dopamine signaling and differ from competing antipsychotics.
-
Anthropic Opens Wet Lab to Test Claude in Biology Experiments
Anthropic has opened a Bay Area wet lab to test how Claude and the Model Hardware Standard can connect AI reasoning with physical biology experiments.
-
Eli Lilly’s Inluriyo–Verzenio Combination Wins FDA Approval in ESR1-Mutated Breast Cancer
The FDA approved Eli Lilly’s Inluriyo plus Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. In an exploratory EMBER-3 analysis, median progression-free survival was 11.1 months with the combination versus 5.5 months with Inluriyo alone.
-
How Inluriyo and Verzenio Deliver Dual Blockade in ESR1-Mutated Breast Cancer
Inluriyo and Verzenio target two connected drivers of ESR1-mutated breast cancer. Inluriyo degrades estrogen receptor alpha to suppress estrogen-dependent transcription, while Verzenio inhibits CDK4/6 to block downstream cell-cycle progression.
-
BioNTech’s Gotistobart Posts 18.5-Month Median Survival in Squamous NSCLC
Gotistobart achieved median overall survival of 18.5 months versus 10.0 months with docetaxel in the non-pivotal stage 1 portion of PRESERVE-003.
-
GSK Plans First-Line Jideytro Filing After 94% Response Rate
GSK plans to seek first-line FDA approval for Jideytro after the ROS1 inhibitor achieved a 94% response rate in 94 TKI-naïve patients in the ARROS-1 study.
-
How Jideytro Blocks ROS1 Fusion Signaling in Lung Cancer
Jideytro is a brain-penetrant, TRK-sparing macrocyclic inhibitor designed to block ROS1 fusion signaling and resistant variants such as G2032R.